CMS granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026, removing a major access barrier for comprehensive genomic profiling in solid tumors. The decision covers the FDA‑approved assay and will likely accelerate adoption of tissue‑based comprehensive genomic profiling in oncology clinics. Separately, Guardant and Merck announced a multi‑year agreement to use Guardant’s liquid and tissue biopsy tests to support enrollment in Merck clinical trials. The partnership will integrate genomic testing into trial screening and patient selection across Merck’s oncology programs. Together, the reimbursement and diagnostic partnership highlight a convergence of payer support and industry collaboration that can accelerate precision oncology trials and commercialization. Clinical teams will need to align testing workflows, companion diagnostic claims, and payer coding. Sources: company announcements and CMS notice summarized in the original coverage.